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Introduction: Topical glyceryl trinitrate (GTN) has gained popularity as a treatment for anal
fissure in the West. In our country, lignocaine is still the current treatment for the entity.
This study was done to compare the effect of GTN with lignocaine in terms of healing rate
and recurrence in South Asian population.
Methods: A prospective, double blinded, randomised controlled trial was conducted on 50
patients (both treatment arms included) of all ages and either gender with a clinical diag-
nosis of anal fissure. Group A was given 0.2% GTN ointment and Group B was given ligno-
caine ointment. Both subjective and objective signs of healing were assessed and adverse
effects of the treatment were sought.
Results: Symptomatic relief was earlier with GTN as compared with lignocaine. Pain relief
was steady and sustained in those treated with GTN but returned to pre-treatment status
within 5 weeks in patients with lignocaine. After 8 weeks of treatment, 80% of patients in
Group A showed clinical signs of healing compared to 32% in Group B ( p¼ 0.001). Headache
was the main side effect of GTN. At 6-month follow-up, recurrence was seen in 3/8 patients
in Group B compared to 8/20 in the GTN Group ( p¼ 1).
Conclusion: Topical GTN has earlier and a higher rate of clinical healing of anal fissure with
acceptable side effects. The recurrence rate is high and comparable to lignocaine ointment.
It is a safe and an effective treatment of anal fissure in a South Asian population.
ª 2007 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Anal fissure is a tear in the anoderm that eventually becomes
an ulcer. It causes suffering out of proportion to the size of the
lesion. Spasm of internal anal sphincter has long been ob-
served in patients with anal fissure and that it leads to high
maximum resting anal pressure (MRP).1 In recent angio-
graphic studies, it was found that the small branches of infe-
rior rectal artery pass through the intermuscular septa of the
internal anal sphincter and that the posterior wall of analcanal is less well perfused than the anterior.2 In this way
a high MRP secondary to internal anal sphincter (IAS) spasm
compounded by ischaemia of posterior anal commissure
leads to increased prevalence and chronicity of anal fissure
at the posterior midline of the anal canal.3
A search for non-surgical treatment of anal fissure had led
to the exploration of novel drugs like glyceryl trinitrate (0.2%
GTN),4 calcium channel blockers, alpha-1 adrenoceptor
blockers and botulinum toxin, all with varied success. Most
of the studies on the efficacy of GTN for anal fissure are* Corresponding author. 21 Erinvale Gardens, Belfast, BT10 0FS, NI, UK. Tel.: þ44 7969660815; fax: þ44 2890914250.
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i n t e r n a t i o n a l j o u r n a l o f s u r g e r y 5 ( 2 0 0 7 ) 4 2 9 – 4 3 2430from the Western countries. In our country, the current treat-
ment is lignocaine ointment. The effect of GTN on patients
from our region remains a knowledge gap. This trial was con-
ducted to compare topical GTN cream with topical lignocaine
ointment in the healing of anal fissure and the recurrence rate
at 6 months.
2. Patients and methods
A prospective, double blinded, randomised controlled trial
was conducted at Jinnah Hospital Lahore, Pakistan, a tertiary
referral centre. Approval of the trial was obtained from the
local research ethics committee and the project was regis-
teredwith The College of Physicians and Surgeons of Pakistan.
Fifty consecutive consenting patients of all ages and either
gender with a documented active anal fissure were recruited
in the trial between 2000 and 2001. The diagnosis was entirely
clinical. Patients with perianal fistula, perianal abscess,
inflammatory bowel disease, haemorrhoidectomy in the pre-
ceding year, ischaemic heart disease, migraine and pregnancy
were excluded. Anal pain with an anodermal ulcer for less
than 8 weeks (and absent sentinel tag) was taken as acute
anal fissure, while pain with a non-healing ulcer for more
than 8 weeks was taken as chronic anal fissure (regardless
of presence or otherwise of the sentinel tag). Patientswith pre-
vious treatment for the fissure were included if the end of
treatment was 3 months before inclusion (‘washout period’
more than 3 months). The principal author obtained an in-
formed consent in the outpatient department and rando-
mised the patients into two groups (Group A and Group B)
(Fig. 1) by choosing a colour-coded card in thick white enve-
lopes. Neither the patient nor the examining consultant was
aware of the treatment offered to the particular patient. Group
A received 0.2% GTN ointment and Group B received 5% ligno-
caine ointment (the prevalent treatment for anal fissure at the
time). The patientswere asked to apply a pea-sized quantity of
the given ointment to the anal margin, twice daily for a period
of 8 weeks. A ‘visual analogue scale for (VAS) pain’ scorecard
was devised by drawing a straight line between two points
taken as 1 and 10. The scale was then equally divided into
10 points. Patients were asked to give 1 point to no pain and
10 points for theworst pain they ever experienced. All patients
were advised to keep an accurate record of their pain score
daily by using the VAS scorecard. General advice included
high fibre and judicious fluid intake with avoidance of strain-
ing at defecation. Compliance was determined by subjective
enquiry.
Follow-up was arranged at the end of week number 1, 2, 8
and at 6 months. Clinical healing was accepted if two out of
three criteria were met from first, self-reported (defecatory)
VAS pain score of less than two, second, normal clinical exam-
ination (parting the buttocks, effacement of anal verge, digital
anorectal exam and anoscopy) and third, epithelialisation or
disappearance of the fissure. Clinical signs of healing were
assessed by a consultant blinded to the mode intervention.
The primary outcome measure was clinical healing at the
8-week follow-up. The secondary outcome measure was re-
lapse of the fissure at 24 weeks (6 months). It was an inten-
tion-to-treat analysis. Patients whose fissures had nothealed following treatment with one intervention were
offered the other or surgical treatment (examination under
anaesthetic, fissurectomy or internal anal sphincterotomy).
2.1. Statistical analysis
The power was calculated with alpha value of 0.05, beta value
of 80% and a difference of 40% in the healing rate. It was based
on the expected result of 50% heal rate with lignocaine and
90% with GTN. It calculated 24 patients per treatment arm
(total sample¼ 48). The mean and median with interquartile
range (iqr) were calculated. Odds ratio (OR) was calculated
for each group. Data were compared using Fisher’s exact
test. For pain score comparison within the respective group
and between Groups A and B, Wilcoxon’s signed rank test
and the Mann–Whitney U test were applied. For all estima-
tions, p-value of <0.05 was considered significant, Microsoft
Excel 2000 and SPSS software were used to construct graphs.
3. Results
A total of 50 patients were randomised into two groups, Group
A (0.2% GTN, n¼ 25) and Group B (lignocaine, n¼ 25) (Fig. 1).
Thirty-two patients were male and 18 female (M:F¼ 1.7:1).
Patients with anal fissure
n=50
Randomised
Patient=blinded
Physician=blinded
Assessor=blinded
Follow up at:
week 1 n=25
week 2 n=25
week 8 n=25
6 months n=23
Follow up at:
week 1 n=25
week 2 n=25
week 8 n=25
6 months n=22
Group A n=25
0.2%GTN
topical bd x8/52
Group B n=25
Lignocaine
topical bd x8/52 
Follow up at 6 months=45/50 90%
Fig. 1 – Outline of the study.
i n t e rn a t i o n a l j o u rn a l o f s u r g e r y 5 ( 2 0 0 7 ) 4 2 9 – 4 3 2 431Age ranged fromnine to 58 years (mean¼ 31.28,median¼ 32.5,
iqr¼ 23–37.75). The demographic data at the start of the
trial are shown in Table 1. After 8 weeks of treatment,
the fissure had healed in 20/25 (80%) patients in Group A
(GTN) compared to 8/25 (32%) in Group B (lignocaine)
( p¼ 0.00144) (Fig. 2). Symptomatic relief was earlier and
sustained in GTN group of patients. Patients who were
given lignocaine ointment also showed a subjective im-
provement initially but their pain scores returned towards
the pre-treatment levels by the end of second week.
Ninety percent of patients kept an accurate record of their
pain scores on the VAS.
The pre-intervention VAS scores in the two groups were
comparable ( p¼ 0.0808). At 8 weeks post-intervention the
GTN group has significant improvement in the VAS scores
than the lignocaine group (mean VAS 2.44 for Group A vs.
5.4 for Group B; p¼<0.001) (Fig. 2).
Significantly more patients in GTN treatment arm com-
plained of headache compared to lignocaine (17 vs. 7; p¼ 0.01)
Table 2. It was mild and responded well to paracetamol. None
of the participants had to stop the treatment because of the
headache. Forty-five patients (90%) were reviewed at 6 months
for signs of recurrence. Three out of eight (37.5%) patients in
Group B who had healed on lignocaine had a recurrence of
analfissure, comparedwitheightoutof20 (40%)whohadhealed
followingGTNtreatment ( p¼ 1) (Fig. 3).All recurrenceswere of-
fered surgical treatment at that point.
4. Discussion
GTN has proved its efficacy in the developed world as a first
line treatment for anal fissure. This trial was conducted to
Table 1 – Demographic details
Group A (GTN) Group B (lignocaine)
n 25 25
M:F 1.7:1 1.7:1
Median age 36 years (iqr¼ 26–42) 33 years (iqr¼ 22–37)
Acute fissures 9 9
Chronic fissures 16 16
Mean VAS score 5.6 5.04
Oddsof fissure healing at 8 weeks
Odds ratio (OR)=8.5 ci 2.337-39.905 RR=2.5 p=0.00144
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Fig. 2 – Fissure healing at the 8-week follow-up.evaluate its effectiveness in an entirely different social, eco-
nomical, cultural and political setting in Pakistan and it con-
firms that GTN is an effective and a safe treatment for anal
fissure.
The staple diet of Pakistanis is rich in fibre and comprises
of fresh fruit and vegetables. Obesity, diverticular disease
and inflammatory bowel disease are uncommon but constipa-
tion remains an everyday problem for the masses.
This study shows a prevalence of anal fissure inmaleswith
more patients presenting with chronic anal fissure. This find-
ing partly reflects the social and cultural limitations, as most
of the population does not want their pudenda to be exam-
ined. The chronicity of the disease reflects the general public
attitude as they try alternative therapies before attending
a medically qualified doctor. Eighty percent of patients in
this trial were successfully treated with GTN as compared to
32% with lignocaine. These figures are comparable with the
international studies reporting healing rate of 65–90%.5,6,9–11
It has been reported that higher doses than 0.2% GTN are
not more effective.7
VAS for pain was a simple and an effective way to evaluate
the subjective improvement of therapy and it was seen that on
most occasions the pain scores fell progressively and perma-
nently as the treatment continued with GTN. In some patients
on lignocaine treatment, pain was relieved initially, but then
returned close to the pre-treatment levels within 5 weeks.
These findings were similar to those by Lund as he noted fail-
ure of the placebo after 4 weeks.5 Out of the 17 patients who
did not heal in Group B, 12 (71%) showed both subjective and
objective signs of improvement with 8 weeks of GTN
treatment.
The mean healing time of 4.1 weeks (2–8 weeks) was ob-
served in this study, which is comparable to the results in
theWest5 where the healing time was between 2 and 6 weeks.
Table 2 – Effects of the treatment
Outcome Group A
(GTN),
n¼ 25
Group B
(lignocaine),
n¼ 25
p-Value
Healing at 8 weeks 20 (80%) 8 (32%) p< 0.002
Side effects
Headache 17 (68%) 7 (28%) p¼ 0.01
Pruritis ani 2 (8%) 4 (16%) Not significant
Postural hypotension 1 (4%) 0 Not significant
Odds of fissure recurrence at 6 months (from healed patients)
Odds ratio (OR)=1.111 ci 0.2054-6.008 RR=1.066 p=0.9999
1.111
0.6
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Fig. 3 – Recurrence of fissure at 6-month follow-up.
i n t e r n a t i o n a l j o u r n a l o f s u r g e r y 5 ( 2 0 0 7 ) 4 2 9 – 4 3 2432A recurrence rate of 40%was observed in patients treatedwith
GTN at the 6-month follow-up which is higher than the pub-
lished international research data.5,8 This may be due to
excessive laxative consumption and poor bowel habit but
remains unconfirmed.
Two shortcomings were observed towards the end of the
study. First, for isolated assessment of the acute or of chronic
fissures, the sample size was not sufficient and preferably
should have been considered at the commencement of the
trial. Due to the chronicity and the cross scarring of the
chronic fissures, selection bias may have resulted.
Second, whereas the assessor at the follow-up was blinded
to the type of intervention received, it was preferable if there
was a second blinded assessor to counter inter-observer vari-
ation as the outcome parameter was being measured subjec-
tively. Nevertheless this trial has yielded clinically beneficial
information.
5. Conclusion
In the treatment of a mix of acute and chronic anal fissure pa-
tients, topical GTN has a statistically and clinically significant
success rate for fissure healing and pain improvement at 8
weeks compared to lignocaine ointment (80% vs. 32%). It
came at the cost of clinically acceptable level of morbidity
(headache). The relapse rate at 6 months was high at 37–40%
and was independent of either treatment modality. The effi-
cacy of GTN for anal fissure in a South Asian population is
comparable to that reported in the West.
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